1. Home
  2. CASH vs XERS Comparison

CASH vs XERS Comparison

Compare CASH & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pathward Financial Inc.

CASH

Pathward Financial Inc.

N/A

Current Price

$73.72

Market Cap

1.6B

Sector

Finance

ML Signal

N/A

XERS

Xeris Biopharma Holdings Inc.

N/A

Current Price

$9.28

Market Cap

1.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CASH
XERS
Founded
1954
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.6B
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
CASH
XERS
Price
$73.72
$9.28
Analyst Decision
Buy
Strong Buy
Analyst Count
3
7
Target Price
★ $101.00
$12.29
AVG Volume (30 Days)
181.5K
★ 1.9M
Earning Date
10-20-2026
11-05-2026
Dividend Yield
★ 0.28%
N/A
EPS Growth
N/A
★ 100.00
EPS
★ 6.29
N/A
Revenue
★ $839,894,000.00
$49,590,000.00
Revenue This Year
N/A
$32.77
Revenue Next Year
$5.69
$24.06
P/E Ratio
$11.37
★ N/A
Revenue Growth
11.29
★ 142.67
52 Week Low
$65.93
$5.25
52 Week High
$101.26
$10.09

Technical Indicators

Market Signals
Indicator
CASH
XERS
Relative Strength Index (RSI) 19.64 67.03
Support Level $70.38 $7.15
Resistance Level $84.06 N/A
Average True Range (ATR) 1.49 0.46
MACD -0.38 0.18
Stochastic Oscillator 2.81 85.23

Price Performance

Historical Comparison
CASH
XERS

About CASH Pathward Financial Inc.

Pathward Financial Inc is a unitary savings and loan holding company. It's a wholly owned full-service banking subsidiary of Meta Financial, is both a community-oriented financial institution offering a variety of financial services to meet the needs of the communities it serves, and a payments company providing services on a nationwide basis. It operates through three reportable segments: Consumer: The Consumer segment includes the Partner Solutions business line, which collaborates with partners to navigate payment and lending needs; Commercial: The Commercial segment includes the Company's Commercial Finance business line, which helps businesses access funds needed to launch, operate, and grow; and Corporate Services. The majority of the revenue is generated from Consumer segment.

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.

Share on Social Networks: